A Roche Holding AG study of its experimental breast-cancer drug in combination with another treatment failed to meet the ...
Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its promising drug candidate ...
The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...
Wall Street's verdict on Prasad, generic semaglutide's new pricing, and other biotech news ...
The therapy, mezigdomide, is part of group of medicines the pharma sees as successors to its lucrative multiple myeloma drugs ...
The cancer drug tazemetostat (Tazverik) is being voluntarily withdrawn in the U.S. and all other markets over concerns about secondary cancers, drugmaker Ipsen announced. The company also said it is ...
News-Medical.Net on MSN
Taking anticoagulants alongside prostate cancer drugs does not increase bleeding risk
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
For years, a protein inside our cells has quietly powered billions of dollars' worth of cancer drugs. Now a team of researchers have discovered that this workhorse protein, called cereblon, in ...
Roche said the late-stage trial did not provide reliable evidence that the drug's use in combination with Pfizer's Ibrance ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results